Status:
COMPLETED
Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease
Lead Sponsor:
Onconic Therapeutics Inc.
Conditions:
GERD
Eligibility:
All Genders
19-75 years
Phase:
PHASE2
Brief Summary
Clinical trial to evaluate the safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease
Eligibility Criteria
Inclusion
- Adults between 19 and 75 years old based on the date of written agreement
- Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA Grade A-D on the upper gastrointestinal endoscopy
- Those who experienced symptoms of heartburn or acid reflux within the last 7 days
Exclusion
- Those who have undergone gastric acid suppression or gastric, esophageal surgery
- Those who with clinically significant liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease
- Clinically significant abnormal laboratory values during screening
Key Trial Info
Start Date :
November 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 11 2020
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT04282954
Start Date
November 15 2019
End Date
December 11 2020
Last Update
July 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Hospital and 19 hospitals
Seoul, South Korea